Form 8-K - Current report:
SEC Accession No. 0001193125-20-230054
Filing Date
2020-08-25
Accepted
2020-08-25 17:20:02
Documents
13
Period of Report
2020-08-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d53673d8k.htm   iXBRL 8-K 25305
2 EX-99.1 d53673dex991.htm EX-99.1 65632
  Complete submission text file 0001193125-20-230054.txt   226554

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mnkd-20200821.xsd EX-101.SCH 3081
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnkd-20200821_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnkd-20200821_pre.xml EX-101.PRE 11415
6 EXTRACTED XBRL INSTANCE DOCUMENT d53673d8k_htm.xml XML 3409
Mailing Address 30930 RUSSELL RANCH ROAD SUITE 300 WESTLAKE VILLAGE CA 91362
Business Address 30930 RUSSELL RANCH ROAD SUITE 300 WESTLAKE VILLAGE CA 91362 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50865 | Film No.: 201133262
SIC: 2834 Pharmaceutical Preparations